GW Pharmaceuticals Share Price - GWPH

126.95
1.26 (1.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
GW Pharmaceuticals PLC GWPH NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-2.87 -2.23% 125.69 123.80 128.9195 128.70 128.56 00:00:04
Bid Price Ask Price Spread Spread % News
123.00 132.59 9.59 7.23% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
5,636 398,991  125.47  50,059,653 572,388
Last Trade Time Type Quantity Stock Price Currency
19:06:36 11  126.95 USD

GW Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
 3.89B 30.91M  -71.91M -10.82 3,115.68 22.14M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News GW Pharmaceuticals

Loading Messages....

Latest GWPH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

GWPH Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.


Your Recent History
NASDAQ
GWPH
GW Pharmac..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.